Materialise NV ( MTLS) Stock. Should you Buy or Sell? $ 12.67
0.36 (2.76 %)
Materialise NV Analysis
Updated on 10-09-2022Symbol | MTLS |
Price | $12.67 |
Beta | 0.716 |
Volume Avg. | $183.99 thousand |
Market Cap | $748.33 M |
52 Week Range | $11.13 - $27.55 |
Materialise NV opened the day at $12.67 which is +'2.76 % on yesterday's close. Materialise NV has a 52 week high of $27.55 and 52 week low of $11.13, which is a difference of $16.42. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $748.33 M and total net profit is $205450000 which means the company is trading at 3.64 times profit to market capitalization. Theoretically, if you were to buy Materialise NV for $748.33 M, it would take 15 years to get your money back. Materialise NV are in the Software—Application space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Materialise NV Stock Forecast - Is Materialise NV a Buy or Sell?
DCF Score | Strong Buy | |
ROE Score | Neutral | |
ROA Score | Neutral | |
DE Score | Buy | |
PE Score | Strong Buy | |
PB Score | Strong Buy | |
Overall Recommendation | Strong Buy |
Growth and Value
PE Ratio | 50.680 |
Dividend Yiel | 0.000 |
Net Profit Margin | 0.066 |
Valuing Materialise NV
Price Book Value Ratio | 2.708 | Price To Book Ratio | 2.708 |
Price To Sales Ratio | 2.888 | Price Earnings Ratio | 43.987 |
How liquid is Materialise NV
Current Ratio | 2.269 |
Quick Ratio | 2.057 |
Debt
Debt Ratio | 0.440 | Debt Equity Ratio | 0.787 |
Long Term Debt To Capitalization | 0.227 | Total Debt To Capitalization | 0.278 |
Latest news about Materialise NV

Materialise NV (NASDAQ:MTLS ) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Harriet Fried – Investor Relations-LHA Fried Vancraen – Founder and Chief Executive Officer Peter Leys – Executive Chairman Johan Albrecht – Chief Financial Officer Conference Call Participants Jason Celino – KeyBanc Noelle Dilts – Stifel Operator Good day. And thank you for standing by.

Materialise (MTLS) delivered earnings and revenue surprises of 0% and 4.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ARKK has started selling shares of the software company Materialise. Flagship ETF owns more than 7% of MTLS outstanding shares.

Getting rid of fundamentally weak toxic stocks is important to shield your portfolio from losses. MSGE, MTLS, INNV and LGND are a few toxic stocks according to our model that you should dump now.

Materialise NV (NASDAQ:MTLS ) Q1 2022 Earnings Conference Call April 28, 2022 8:30 AM ET Company Participants Harriet Fried - IR Peter Leys - Executive Chairman Johan Albrecht - EVP & CFO Wilfried Vancraen - Founder, CEO & Director Conference Call Participants Jacob Stephan - Lake Street Capital Noelle Dilts - Stifel, Nicolaus & Company Gregory Ramirez - Bryan Garnier & Co Ltd Jason Celino - KeyBanc Capital Markets Operator Good day, and thank you for standing by. Welcome to the Q1 2022 Materialise Financial Results Conference Call.
About Materialise NV
Description :
Materialise NV provides additive manufacturing and medical software, and 3D printing services in the Americas, Europe and Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. Its Materialise Software segment offers software through programs and platforms that enable and enhance the functionality of 3D printers and of 3D printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, Website, and third-party distributors. The company's Materialise Medical segment provides medical software that allows medical-image based analysis and engineering, as well as patient-specific design of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies through its direct sales force, Website, and picture archiving and communication system partners. Its Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to industrial and commercial customers. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.